SEC Form 4 · accession 0001140361-16-069909

PLUS THERAPEUTICS, INC. · CNSY

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Officer — VP and GM Cell Therapy

Period of report

Jun 15, 2016

Accepted (ET)

Jun 15, 2016 · 6:52 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001095981

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock^F1	Jun 15, 2016	X	2,500	—	A	4,500	D

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Subscription Rights (Right to Buy)^F1	$2.55	Jun 15, 2016	X	2,500	D	May 26, 2016	Jun 10, 2016	See Footnote	2,500	0	D
Warrants (Right to Buy)^F1,F2	$3.06	Jun 15, 2016	X	1,250	A	Jun 15, 2016	Dec 14, 2018	Common Stock	1,250	1,250	D

F1The common stock and the warrants reported on this Form 4 were acquired pursuant to the exercise of subscription rights previously distributed by Cytori Therapeutics, Inc. (the "Company) to all holders of the Company's common stock. The subscription rights entitled each recipient thereof to purchase units ("Units"). Each Unit consists of one share of the Company's common stock and 0.5 of a warrant, with each warrant representing the right to purchase one share of the Company's common stock. The purchase price for each Unit was $2.55.
F2Each warrant entitles the holder to purchase one share of the Company's common stock at an exercise price of $3.06 from the date of issuance through December 14, 2018.